Evaluacion de la capacidad inmunogénica de la vacuna antirrábica tipo Fuenzalida- Palacios (CRL) y de la vacuna antirrábica de cultivo celular (Verorab®) en personas con tratamiento preexposición
| Autor: | Myriam Favi C, Attia Acevedo A, Rodrigo Trujillo M, Orietta Roos K, Luis Rodríguez A, Verónica Yung P |
|---|---|
| Jazyk: | Spanish; Castilian |
| Rok vydání: | 2004 |
| Předmět: | |
| Zdroj: | Revista médica de Chile v.132 n.1 2004 SciELO Chile CONICYT Chile instacron:CONICYT |
| Popis: | A WHO experts committee recommended the substitution of antirabic vaccines produced in nervous tissue, by vaccines produced in tissue cultures. Aim: To compare the immunogenic capacity of antirabic vaccines CRL (produced in nervous tissue) and Verorab® (produced in tissue culture), used for pre-exposure prophylaxis in humans. Patients and methods: Fifty four volunteers were immunized for this study. The first group, vaccinated with CLR was treated with a scheme of 4 subcutaneous peri umbilical doses in days 0, 3, 7 and 28. The second group, vaccinated with Verorab® vaccine was treated with a scheme of 3 intramuscular doses in deltoid zone at days 0, 7 and 28. Blood samples were obtained at days 0, 7, 42 and 365 to measure neutralizing antibodies using the Inhibition of Fluorescent Focus Technique (RFFIT). Results: At day seven, a primary non protective immunologic response was observed in both groups, with titers significantly higher in the group vaccinated with Verorab®. At day 42, no differences were observed. At day 365, all subjects vaccinated with Verorab® and 50% of individuals vaccinated with CRL had protective antibody titers (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|